REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.76
-0.03 (-0.34%)
Nov 4, 2024, 4:00 PM EST - Market closed
REGENXBIO Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for REGENXBIO stock have an average target of 37.7, with a low estimate of 18 and a high estimate of 52. The average target predicts an increase of 330.37% from the current stock price of 8.76.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for REGENXBIO stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 6 | 6 | 6 | 5 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $52 | Strong Buy | Maintains | $52 | +493.61% | Oct 22, 2024 |
| Raymond James | Raymond James | Buy Initiates $18 | Buy | Initiates | $18 | +105.48% | Oct 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $39 | Strong Buy | Reiterates | $39 | +345.21% | Sep 4, 2024 |
| Barclays | Barclays | Buy Maintains $55 → $50 | Buy | Maintains | $55 → $50 | +470.78% | Aug 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $38 → $39 | Strong Buy | Maintains | $38 → $39 | +345.21% | Aug 5, 2024 |
Financial Forecast
Revenue This Year
97.32M
from 90.24M
Increased by 7.85%
Revenue Next Year
308.53M
from 97.32M
Increased by 217.02%
EPS This Year
-4.74
from -6.02
EPS Next Year
-0.99
from -4.74
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 147.8M | 422.7M | 627.9M | ||
| Avg | 97.3M | 308.5M | 271.8M | ||
| Low | 66.6M | 195.0M | 103.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 63.8% | 334.4% | 103.5% | ||
| Avg | 7.8% | 217.0% | -11.9% | ||
| Low | -26.2% | 100.4% | -66.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.53 | 1.87 | -2.51 | ||
| Avg | -4.74 | -0.99 | -3.34 | ||
| Low | -4.89 | -3.08 | -4.28 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.